Search
Search through the thousands of lawsuits, complaints and recalls on our site.

Drugs / Medicines Recalls and Alerts

Report Fraud

FDA Issues Guidance on Hospital Bed Design to Reduce Patient Entrapment

Date: 3/24/2006
Reason: Entrapment can occur when part of a patient's body becomes caught between parts of the bed, such as in the space between the mattress and the side rail. This can cause strangulation and death.
Distribution: Nationwide.

Need Legal Help?

Does this recall or safety alert affect you or your family?

Media Inquiries:
Stephen King, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

The Food and Drug Administration (FDA) published final guidance designed to reduce the occurrence of hospital bed entrapments. Entrapment can occur when part of a patient's body becomes caught between parts of the bed, such as in the space between the mattress and the side rail. This can cause strangulation and death. This guidance was prepared using input from both government and private sector groups.

The guidance, entitled "Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment" identifies special issues associated with hospital bed systems and provides design recommendations for manufacturers of new hospital beds and suggestions for health care facilities on ways to assess existing beds. The guidance characterizes the body parts at risk for entrapment, identifies the locations of hospital bed openings that are potential entrapment areas, recommends dimensional criteria for new hospital bed systems, provides information about reporting entrapment adverse events, and includes a description of recommended test methods for assessing gaps in hospital bed systems.

Key body parts at risk of entrapment are:

Head
Neck
Chest
 Potential zones of entrapment in a hospital bed system are:

1.Within the rail
2. Under the rail, between the rail supports or next to a single rail support
3. Between the rail and the mattress 
4. Between the rail, at the ends of the rail 
5. Between split bed rails 
6. Between the end of the rail and the side edge of the head or foot board 
7. Between the head or foot board and the mattress end

This guidance is the result of a years-long partnership between the FDA and the Veterans Administration, Health Canada's Medical Devices Bureau, representatives from national health care organizations and provider groups, patient advocacy groups, and medical bed and equipment manufacturers, who formed a working group in 1999 known as the Hospital Bed Safety Workgroup (HBSW). The HBSW also worked in cooperation with the Joint Commission on Accreditation of Healthcare Organizations, the Center for Medicare & Medicaid Services, and the Consumer Product Safety Commission to improve patient safety associated with the use of hospital beds.

FDA has received approximately 691 entrapment reports over a period of 21 years from January 1, 1985 to January 1, 2006 . In these reports, 413 people died, 120 were injured, and 158 were near-miss events with no serious injury as a result of intervention. These entrapment events have occurred in openings within the bed rails, between the bed rails and mattresses, under bed rails, between split rails, and between the bed rails and the head or foot boards. Elderly patients in hospitals and nursing homes, especially those who are frail, confused, restless, or who have uncontrollable body movement, are most vulnerable to entrapment. Entrapments have occurred in a variety of patient care settings, including hospitals, nursing homes, and private homes. Long-term care facilities reported the majority of the entrapments.

"While these numbers appear small, we believe they are signals about significant adverse events. Often, adverse events such as these go unreported to the FDA making it likely our counts of these tragic adverse incidents is lower than the number that actually occurs," said Dr. Kessler.

The final guidance, "Guidance for Industry and FDA Staff; Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment," is available on FDA's website at: http://www.fda.gov/cdrh/beds/.

 


Other Drugs / Medicines Recalls and Alerts of Interest

Date: 6/12/2008
Reason: Limited lots of Carmeda-coated products were manufactured with heparin found to have been contaminated with oversulfated chondroitin sulfate (OSCS).

Distribution: Nationwide
 
Date: 6/16/2008
Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate

Distribution: Nationwide
 
Date: 6/12/2008

Reason: Taking AZASAN® instead of SOLODYN® presents a health hazard and safety risk to patients

Distribution: Nationwide

 
Date: 6/12/2008
Reason: it contained a potentially harmful undeclared ingredient, hydroxyhomosildenafil

Distribution: Nationwide
 
Date: 6/12/2008

Reason: Oversized tablets may contain as much as two times the labeled level of active morphine sulfate

Distribution: Nationwide

 
Date: 6/12/2008
Reason: Limited lots of Atrium heparin-coated Hydraglide Thoracic Catheters were manufactured with heparin found to have been contaminated with oversulfated chondroitin sulfate (OSCS)

Distribution: Nationwide
 

Become a LawCash Member - FREE!
'Find Money' E-Book
Weekly Email Alerts




privacy policy
YouNewz Beta
IT'S FREE

Report

Report Newz and easily upload your own newzworthy photos from your cell phone or computer to the web.

Share

Quickly share your photos with family, friends, co-workers, or the world with your own Newzpaper.

Read

Instantly find Newz and photos from other YouNewzers and read other YouNewzers Newzpapers.
 
Class Action Lawsuit Center || Product Recall Center || Consumer Complaint Center || About LawCash Link Exchange
Privacy Policy || Legal Policies || Terms & Conditions || Website Advertising Policy || Site Map || Top Lawsuits
LawCash® is a service of nola3, llc
© 2000 - 2008 Copyright. All rights reserved nola3, llc.

[ Home ]
LawCash
login
Justice is a click away.